Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ: EWTX )

14.83 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18
Open 14.83
Bid (Size) 13.10 (1)
Ask (Size) 14.94 (1)
Prev. Close 14.83
Today's Range 14.83 - 14.83
52wk Range 10.60 - 38.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
Via Benzinga

Performance

YTD
-45.14%
-45.14%
1 Month
-36.54%
-36.54%
3 Month
-45.36%
-45.36%
6 Month
-57.40%
-57.40%
1 Year
-5.24%
-5.24%

More News

Read More
Top movers in Wednesday's session
Via Chartmill
These stocks are moving in today's session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Via Benzinga
These stocks are moving in today's pre-market session
Via Chartmill
Why Edgewise Therapeutics (EWTX) Stock Is Falling
Via Benzinga
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics, Inc.
Via Business Wire
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Edgewise Therapeutics
Via Business Wire
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Eyes Worst Losing Streak Since 2018
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
From Edgewise Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.